Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 EBITDA Margin % is 23.05% as of Jun. 2026, which is 26% below its 10-year median of 31.12. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 957 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 83.49% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Prestige Consumer Healthcare EBITDA Margin % Related Terms
Prestige Consumer Healthcare EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBH vs BCRX, AMLX, SUPN: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (PBH) has a EBITDA Margin % of 23.05% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prestige Consumer Healthcare and its competitors. This is 26% below median its historical median of 31.12. Over the past decade, Prestige Consumer Healthcare's EBITDA Margin % has ranged from 0.70 to 33.56. According to the industry distribution chart, Prestige Consumer Healthcare ranks #158 out of 957 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is Prestige Consumer Healthcare's EBITDA Margin % too high?
Prestige Consumer Healthcare's current EBITDA Margin % of 23.05% is 26% below median its 10-year median of 31.12. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 33.56. The Drug Manufacturers industry median EBITDA Margin % is 12.14. Prestige Consumer Healthcare's value of 23.05% is 89.9% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #158 out of 957 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's EBITDA Margin % compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #158 out of 957 companies for EBITDA Margin %. This places Prestige Consumer Healthcare in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.14. Prestige Consumer Healthcare's value of 23.05% is 89.9% above this benchmark. Historically, Prestige Consumer Healthcare's own EBITDA Margin % has ranged from 0.70 to 33.56 over the past decade. While the company's 10-year median is 31.12 vs. the industry median of 12.14, Prestige Consumer Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.14, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current EBITDA Margin % of 23.05% is 89.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current EBITDA Margin % is 23.05%, which is 26% below median its own 10-year median of 31.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current EBITDA Margin % is 23.05%, which is 26% below median its 10-year median of 31.12 and 89.9% above the Drug Manufacturers industry median of 12.14. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current EBITDA Margin % is 23.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
EBITDA Margin %: 23.05% (26% below median its 10-year median of 31.12)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 89.9% above the Drug Manufacturers median (#158 of 957)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
